Please use this identifier to cite or link to this item: https://doi.org/10.1007/s12072-008-9058-1
DC FieldValue
dc.titleA randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)
dc.contributor.authorLee, Y.-M.
dc.contributor.authorSutedja, D.S.
dc.contributor.authorWai, C.-T.
dc.contributor.authorDan, Y.-Y.
dc.contributor.authorAung, M.-O.
dc.contributor.authorZhou, L.
dc.contributor.authorCheng, C.-L.
dc.contributor.authorWee, A.
dc.contributor.authorLim, S.-G.
dc.date.accessioned2016-11-08T09:58:06Z
dc.date.available2016-11-08T09:58:06Z
dc.date.issued2008-06
dc.identifier.citationLee, Y.-M., Sutedja, D.S., Wai, C.-T., Dan, Y.-Y., Aung, M.-O., Zhou, L., Cheng, C.-L., Wee, A., Lim, S.-G. (2008-06). A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatology International 2 (2) : 196-201. ScholarBank@NUS Repository. https://doi.org/10.1007/s12072-008-9058-1
dc.identifier.issn19360533
dc.identifier.urihttp://scholarbank.nus.edu.sg/handle/10635/129746
dc.description.abstractPurpose: Tumor necrosis factor-α (TNF-α) is implicated in non-alcoholic steatohepatitis (NASH). Pentoxifylline inhibits TNF-α. We wanted to evaluate the efficacy of Pentoxifylline on NASH patients. Methods: Patients with biopsy proven NASH and persistently elevated alanine aminotransferase (ALT) greater than 1.5 times the upper limit of normal were randomized to 3 months of treatment with a step 1 American Heart Association diet and daily exercise with Pentoxifylline or placebo. Liver function tests, serum lipids and TNF-α, Interleukin 6 (IL-6), and plasma hyaluronic acid were measured at baseline, at weeks 6 and 12. Categorical data were analyzed by Fisher's exact test while independent sample t-test and Mann-Whitney test were used for continuous data. Results: Eleven patients were randomized into the Pentoxifylline and nine to the placebo group. After 3 months of treatment body mass index (BMI), ALT and aspartate aminotransferase (AST) decreased significantly in both groups. There was no difference between the two groups in reduction of BMI (P = 0.897). There was significantly greater reduction in AST in the Pentoxifylline group (P = 0.038). There was a trend toward lower ALT level (P = 0.065) in the Pentoxifylline group. TNF-α and IL-6 decreased significantly in both groups after treatment, but there was no significant difference between the two groups. Conclusion: Three months of Pentoxifylline treatment in combination with diet and exercise results in significantly greater reduction in AST levels in patients with NASH as compared with controls. © Asian Pacific Association for the Study of the Liver 2008.
dc.description.urihttp://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.1007/s12072-008-9058-1
dc.sourceScopus
dc.subjectNon-alcoholic steatohepatitis
dc.subjectPentoxifylline
dc.subjectRandomized controlled study
dc.subjectTNFalpha
dc.typeArticle
dc.contributor.departmentMEDICINE
dc.description.doi10.1007/s12072-008-9058-1
dc.description.sourcetitleHepatology International
dc.description.volume2
dc.description.issue2
dc.description.page196-201
dc.identifier.isiut000257814200009
Appears in Collections:Staff Publications

Show simple item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

54
checked on Oct 23, 2020

WEB OF SCIENCETM
Citations

54
checked on Oct 15, 2020

Page view(s)

87
checked on Oct 17, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.